LivingGLP1
Study S001448

Biometabolic Impact of Continuation of GLP-1 Agonists Following Bariatric

ClinicalTrials.gov record

Registration

Registration
NCT06132477
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE4
Masking
NONE
Status
RECRUITING
Enrollment
150
Start
2024-02-01
Primary completion
2028-07
Lead sponsor
University of Missouri-Columbia
Conditions
Morbid Obesity; Metabolic Syndrome; Diabetes Mellitus; Hypertension; Obstructive Sleep Apnea of Adult
Interventions
DRUG:GLP-1 receptor agonist
Results posted
FALSE
Individual participant data sharing
UNDECIDED

Registered primary outcomes

  • Effect of GLP1-RA on weight loss [6 months]
  • Effect of GLP1-RA on circulating bile acids and metabolites [6 months]
  • Effector of GLP1-RA on gut microbiome diversity [6 months]
  • Effect of GLP1-RA on satiety and hunger [6 months]
  • Effect of GLP1-RA on Glycemic control [6 months]

Linked records (9)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0006534Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.
Jensen AB, Obesity surgery
2023Randomized trialPMID 36765019DOIregistry reference BACKGROUND:36765019
R0013078The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review.
Llewellyn DC, Obesity (Silver Spring, Md.)
2023Systematic reviewPMID 36502288DOIregistry reference BACKGROUND:36502288
R0008141Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta-analysis.
Sarma S, Obesity (Silver Spring, Md.)
2022Systematic reviewPMID 36321278DOIregistry reference BACKGROUND:36321278
R0008060Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
Jendle J, Cardiovascular diabetology
2021Randomized trialPMID 34920733DOIregistry reference BACKGROUND:34920733
R0024162Liraglutide Augments Weight Loss After Laparoscopic Sleeve Gastrectomy: a Randomised, Double-Blind, Placebo-Control Study.
Thakur U, Obesity surgery
2021Randomized trialPMID 32656729DOIregistry reference BACKGROUND:32656729
R0021400Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice.
Madsen MSA, Scientific reports
2019PreclinicalPMID 31666597DOIregistry reference BACKGROUND:31666597
R0025356Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
Blundell J, Diabetes, obesity & metabolism
2017Randomized trialPMID 28266779DOIregistry reference BACKGROUND:28266779
R0006628Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
Madsbad S, Diabetes, obesity & metabolism
2016Other trialPMID 26511102DOIregistry reference BACKGROUND:26511102
R0025439Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
Astrup A, International journal of obesity (2005)
2012Randomized trialPMID 21844879DOIregistry reference BACKGROUND:21844879